1Hermanek P. Scheibe O, Spiessl B, et al. TNM classification of malignant tumor: new 1987 edition[J]. Langenbecks Arch chir,1987,371(1) :1-2.
2Scoot J.Huskisson E C. Graphic representation of pain[J]. Pain,1976,2(2) :175-184.
3Sloan P A,Moulin D E, Hays H. A clinical evaluation of transdermal therapeutic system fentanyl for the treatment of cancer pain[J].J Pain Symptom Manage, 1998,16(2): 102- 111.
4Radbruch L, Sabatowski R, Loick G, et al. Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine[J]. Palliat Med,2000,14(2): 111 - 119.
4Gibbs M. The role of transdennal fentanyl patches in the effective management of dancer pain [ J ]. Int J Palliat Nurs, 2009,15 ( 7 ) : 354 - 359.
5Hair PI, Keating GM, McKeage K. Transdermal matrix fentanyl membrane patch (matrifen) : in severe cancer -related chronic pain[J].Drugs ,2008,68(14) :2001 - 2009.
6Muijsers RB, Wagstaff AJ. Transdermal fentanyl : an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control[ J]. Drugs,2001,61 (15) :2289-2307.
